Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities

NEXT STORY
Nextech’s InfernoAR Signs Annual License Contract With National Association of Medicaid Directors (NAMD)
PREV STORY
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Targovax announces that TG02 has passed the initial safety review in the first-in-man clinical trial in colorectal cancer

Oslo, Norway, 18 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company ...

author_avatar
NASDAQ Market News

ArTara Therapeutics Announces the Appointment of Richard Levy, M.D., and Gregory Sargen to its Board of Directors

author_avatar
NASDAQ Market News

CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences

author_avatar
NASDAQ Market News